

156. The method of claim 128, wherein the subject is a human or non-human animal.

157. The method of claim 128, which is a prophylactic or therapeutic method.

158. The method of claim 128, wherein the subject is in need of treatment to reduce or deplete adenosine levels and/or increase ubiquinone levels. --

REMARKS

THIS APPLICATION

This application is a divisional of U.S. Patent Application Serial No. 09/841,426, filed April 24, 2001, claiming a composition comprising a DHEA compound for the treatment of chronic obstructive pulmonary disease (COPD). In this application, similar claims have been introduced, where the composition comprises a ubiquinone, and optionally a DHEA agent.


THE CLAIMS

Claims 1-79 were filed with the original patent application, and have been deleted. Claims 80-158 have been added and are now pending in this case. Consideration of these claims is requested.

The amendments to the specification and the abstract are of a clerical nature. The amendments to the claims are fully supported by the specification as filed and by the original claims. No objectionable new matter is believed to have been introduced hereby.

Although no further fee is believed to be owed, the Assistant Commissioner is hereby authorized to charge to PTO Account No. 50-1728, any deficiency in the fees, including an extension fee, which extension, if necessary, is hereby requested. In view of the above amendments and remarks, this application is believed to be in condition for examination and allowance. Early notice to that effect is hereby solicited.

Respectfully submitted.
EpiGenesis Pharmaceuticals, Inc.




Viviana Amzel, Ph.D.
Registration No. 30,930
Attorney for Applicant

October 25, 2001

Date

7 Clarke Drive
Cranbury, NJ 08512
609-409-3035 Direct Ph.
413-254-9245 Fax
email VAmzel@epigene.com

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 and addressed to BOX Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231, on October 25, 2001 by Rashida Haji.



SIGNATURE